Notes
National Health Service
British pounds
Reference
Watt M, et al. Cost-effectiveness of extended-pulse fidaxomicin (EPFX) versus standard vancomycin (SV) in older patients with Clostridium difficile infection in England. 27th European Congress of Clinical Microbiology and Infectious Diseases : (plus poster) abstr. 3748, 22 Apr 2017. Available from: URL: https://distribute.m-anage.com/from.storage?image=rw0T8dJ%2b9af29yIvDR0SNscn2sGC%2b2d242rWF%2fspfoAFOd33HDpqsaMOf%2fFBa0E1%2f1xFv2yvzUGudSTeruHWtw%3d%3d
Rights and permissions
About this article
Cite this article
Expended-pulse fidaxomicin cost effective for CDI in UK. PharmacoEcon Outcomes News 778, 16 (2017). https://doi.org/10.1007/s40274-017-3993-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3993-9